ESSA Pharma Stock Price, News & Analysis (TSE:EPI)

Previous CloseN/A
Today's RangeN/A
52-Week RangeC$0.31 - C$4.60
VolumeN/A
Average Volume43,266 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About ESSA Pharma (TSE:EPI)

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Receive EPI News and Ratings via Email

Sign-up to receive the latest news and ratings for EPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:EPI
CUSIPN/A
Phone+1-778-3310962

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($0.21)
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets130.13%

Miscellaneous

EmployeesN/A
Outstanding Shares29,102,000

ESSA Pharma (TSE:EPI) Frequently Asked Questions

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the Toronto Stock Exchange (TSX) under the ticker symbol "EPI."

Who are some of ESSA Pharma's key competitors?

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the folowing people:

  • Richard M. Glickman LL.D., Chairman of the Board (Age 57)
  • David Ross Parkinson M.D., President, Chief Executive Officer, Director (Age 67)
  • David Wood, Chief Financial Officer (Age 57)
  • Peter Virsik, Chief Operating Officer, Executive Vice President
  • Raymond L. Andersen, Chief Technology Officer, Director (Age 67)
  • Marianne D. Sadar, Chief Scientific Officer, Director (Age 53)
  • Frank Perabo, Chief Medical Officer (Age 50)
  • Franklin M. Berger, Director (Age 67)
  • Scott Requadt J.D., Director
  • Gary Sollis, Director (Age 61)

How do I buy ESSA Pharma stock?

Shares of ESSA Pharma and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 Broadway W Suite 720, VANCOUVER, BC V5Z 1K5, Canada. The company can be reached via phone at +1-778-3310962.


MarketBeat Community Rating for ESSA Pharma (EPI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ESSA Pharma (TSE:EPI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.503.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

ESSA Pharma (TSE:EPI) Consensus Price Target History

Price Target History for ESSA Pharma (TSE:EPI)

ESSA Pharma (TSE:EPI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
9/12/2017Bloom BurtonDowngradeBuy -> HoldView Rating Details
8/2/2017Dawson JamesReiterated RatingBuyView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Earnings History for ESSA Pharma (TSE:EPI)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

ESSA Pharma (TSE:EPI) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ESSA Pharma (TSE:EPI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ESSA Pharma (TSE EPI) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for ESSA Pharma (TSE:EPI)

ESSA Pharma (TSE EPI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/24/2015Robert RiederDirectorBuy3,600C$9.00C$32,389.20
8/31/2015Marianne SadarDirectorSell22,000C$7.60C$167,200.00
(Data available from 1/1/2013 forward)

Headlines

ESSA Pharma (TSE EPI) News Headlines

Source:
DateHeadline
CORRECTION FROM SOURCE: IIROC Trade Resumption - ESSA Pharma Inc.CORRECTION FROM SOURCE: IIROC Trade Resumption - ESSA Pharma Inc.
finance.yahoo.com - December 13 at 9:29 AM
BRIEF-Essa Pharma announces new listing on the TSX Venture Exchange concurrent with voluntary delisting from the TSXBRIEF-Essa Pharma announces new listing on the TSX Venture Exchange concurrent with voluntary delisting from the TSX
www.reuters.com - November 23 at 1:36 AM
Bloom Burton Downgrades ESSA Pharma Inc (EPI) to HoldBloom Burton Downgrades ESSA Pharma Inc (EPI) to Hold
www.americanbankingnews.com - September 13 at 7:18 PM
ESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC and Updates ... - PR Newswire (press release)ESSA Pharma Announces Results from the Phase 1 Clinical Trial of EPI-506 for Treatment of mCRPC and Updates ... - PR Newswire (press release)
www.prnewswire.com - September 13 at 12:15 AM
ESSA Pharma Provides Business Update and Announces Financial Results for the Fiscal Third Quarter Ended June 30, 2017ESSA Pharma Provides Business Update and Announces Financial Results for the Fiscal Third Quarter Ended June 30, 2017
finance.yahoo.com - August 14 at 11:42 PM
ESSA Pharma Inc (EPI) to Release Quarterly Earnings on WednesdayESSA Pharma Inc (EPI) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 9 at 7:02 AM
ESSA Pharma Inc (EPI) Given "Buy" Rating at Dawson JamesESSA Pharma Inc (EPI) Given "Buy" Rating at Dawson James
www.americanbankingnews.com - August 8 at 7:00 AM
BRIEF-Essa Pharma provides further update on proposed equity offeringBRIEF-Essa Pharma provides further update on proposed equity offering
www.reuters.com - July 24 at 10:01 AM
ESSA Pharma Provides Further Update on Proposed Equity OfferingESSA Pharma Provides Further Update on Proposed Equity Offering
finance.yahoo.com - July 24 at 10:01 AM
ESSA Pharma Announces Receipt of NASDAQ Notice of Market Value DeficiencyESSA Pharma Announces Receipt of NASDAQ Notice of Market Value Deficiency
finance.yahoo.com - July 21 at 8:15 PM
ESSA Pharma Announces Receipt of NASDAQ Notice of Bid Price DeficiencyESSA Pharma Announces Receipt of NASDAQ Notice of Bid Price Deficiency
finance.yahoo.com - July 20 at 3:51 PM
ESSA Pharma Announces Overnight Marketed Equity Offering - PR Newswire (press release)ESSA Pharma Announces Overnight Marketed Equity Offering - PR Newswire (press release)
www.prnewswire.com - July 13 at 7:38 PM
ESSA Pharma Announces Pricing of Proposed Equity Offering - PR Newswire (press release)ESSA Pharma Announces Pricing of Proposed Equity Offering - PR Newswire (press release)
www.prnewswire.com - July 13 at 7:38 PM
IIROC Trade Resumption - ESSA Pharma Inc.IIROC Trade Resumption - ESSA Pharma Inc.
finance.yahoo.com - July 13 at 7:38 PM
IIROC Trade Resumption - EPIIIROC Trade Resumption - EPI
finance.yahoo.com - July 13 at 7:38 PM
IIROC Trading Halt - EPIIIROC Trading Halt - EPI
finance.yahoo.com - July 12 at 6:58 PM
ESSA Pharma continues slide; shares down 36% - Seeking AlphaESSA Pharma continues slide; shares down 36% - Seeking Alpha
seekingalpha.com - June 6 at 5:26 PM
ESSA Pharma Presents Data From Phase 1 Trial of EPI-506 at 2017 ASCO Annual Meeting - PR Newswire (press release)ESSA Pharma Presents Data From Phase 1 Trial of EPI-506 at 2017 ASCO Annual Meeting - PR Newswire (press release)
www.prnewswire.com - June 6 at 5:26 PM
ESSA Pharma (EPIX) Says Data from Phase 1 Trial of EPI-506 to be Presented at ASCO - StreetInsider.comESSA Pharma (EPIX) Says Data from Phase 1 Trial of EPI-506 to be Presented at ASCO - StreetInsider.com
www.streetinsider.com - May 19 at 8:01 AM
Form 6-K ESSA Pharma Inc. For: Apr 03 - StreetInsider.comForm 6-K ESSA Pharma Inc. For: Apr 03 - StreetInsider.com
www.streetinsider.com - April 3 at 2:18 PM
ESSA Pharma Provides Business Update and Announces Financial Results for the First Quarter Ended December 31 ... - PR Newswire (press release)ESSA Pharma Provides Business Update and Announces Financial Results for the First Quarter Ended December 31 ... - PR Newswire (press release)
www.prnewswire.com - February 13 at 10:58 PM
10 Biggest Mid-Day Losers For Wednesday10 Biggest Mid-Day Losers For Wednesday
feeds.benzinga.com - December 28 at 1:27 PM

SEC Filings

ESSA Pharma (TSE:EPI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

ESSA Pharma (TSE EPI) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.